Yamauchi, Takayoshi http://orcid.org/0000-0002-5685-7658
Hoki, Toshifumi http://orcid.org/0000-0002-8853-4167
Oba, Takaaki
Jain, Vaibhav
Chen, Hongbin
Attwood, Kristopher
Battaglia, Sebastiano
George, Saby
Chatta, Gurkamal
Puzanov, Igor http://orcid.org/0000-0002-9803-3497
Morrison, Carl
Odunsi, Kunle
Segal, Brahm H. http://orcid.org/0000-0001-5043-7380
Dy, Grace K.
Ernstoff, Marc S. http://orcid.org/0000-0002-8132-7069
Ito, Fumito http://orcid.org/0000-0002-6866-671X
Funding for this research was provided by:
Astellas Foundation for Research on Metabolic Disorders
Uehara Memorial Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA154967, P50CA159981-01A1, R01CA188900, K08CA197966)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Melanoma Research Alliance
Sarcoma Foundation of America
U.S. Department of Health & Human Services | NIH | National Cancer Institute
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (LC180245)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR001412)
Article History
Received: 5 June 2020
Accepted: 1 February 2021
First Online: 3 March 2021
Competing interests
: Igor Puzanov: Amgen consultant. Marc S. Ernstoff receives clinical trial support from Merck, Bristol Myers Squibb, Alkermes, EMD Serono and serves on a BMS DMSC and consultant for ImmuNext, Alkermes, EMD Serono, Merck, and BMS. Kunle Odunsi co-founder of Tactiva Therapeutics and receives research support from Astra Zeneca and Tessaro. Saby George reports consulting fees from and advisory roles for Pfizer, Exelixis, Bristol-Myers Squibb, Sanofi/Genzyme, Genentech, Bayer, Corvus, EMD Serono, Seattle Genetics/Astellas, Eisai, Aveo, and Merck, and institutional grant support from Bristol-Myers Squibb, Novartis, Bayer, Pfizer, Merck, Seattle Genetics/Astellas, Eisai, Calithera Biosciences, Immunomedics, Corvus Pharmaceuticals, Surface Oncology, and Agensys. The remaining authors have no competing interests.